Does Zepbound Cause Hair Loss? A Closer Look at SURMOUNT-1

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• SURMOUNT-1 reported alopecia in 5.7% of tirzepatide 15 mg participants versus 1.0% on placebo
• The dose-response curve (3.5% at 5 mg, 4.9% at 10 mg, 5.7% at 15 mg) tracks with magnitude of weight loss, not drug exposure independent of weight
• Tirzepatide shows roughly twice the alopecia incidence of semaglutide; the difference appears to be weight-loss-mediated rather than mechanism-specific
• Telogen effluvium has a characteristic 2 to 4 month lag, then 3 to 6 months of active shedding, with full recovery in 6 to 12 months after weight stabilizes
• Mounjaro and Zepbound share the same active ingredient (tirzepatide); the hair loss signal applies to both

Direct answer

Yes. The pivotal SURMOUNT-1 trial of tirzepatide reported alopecia (hair loss) in 5.7% of participants taking 15 mg weekly, compared to 1.0% of placebo. Lower doses showed lower but still elevated rates. The clinical pattern matches telogen effluvium, a reversible shedding triggered by rapid weight loss. Tirzepatide shows roughly twice the alopecia rate seen with semaglutide, which is consistent with the larger average weight loss tirzepatide produces.

Table of contents

1. The SURMOUNT-1 numbers in detail
2. Why tirzepatide shows more hair loss than semaglutide
3. The GIP receptor question
4. The dose-response curve and what it means for users
5. Real-world FAERS data and post-marketing signals
6. The clinical presentation in tirzepatide users
7. Comparison: Zepbound vs Wegovy vs compounded options
8. Risk factors that increase Zepbound hair loss probability
9. The contrary view: is there something tirzepatide-specific?
10. Decision framework
11. FAQ
12. Sources

The SURMOUNT-1 numbers in detail

SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine 2022) randomized 2,539 adults with obesity or overweight with a weight-related complication to one of three tirzepatide doses (5, 10, or 15 mg weekly) or placebo for 72 weeks. The published adverse event tables included alopecia data:

Arm	Alopecia incidence	Mean weight loss	Number needed to treat for alopecia
Placebo	1.0%	3.1%	Reference
Tirzepatide 5 mg	3.5%	15.0%	~40
Tirzepatide 10 mg	4.9%	19.5%	~26
Tirzepatide 15 mg	5.7%	22.5%	~21

The relationship is monotonic: higher dose, larger weight loss, more alopecia. The number needed to harm (or in this case, number needed to treat to observe one additional case of alopecia) is roughly 21 at the highest dose, meaning for every 21 patients on 15 mg, one will report alopecia who would not have on placebo.

SURMOUNT-3 and SURMOUNT-4 follow-up trials confirmed similar incidence patterns. SURMOUNT-4 (Aronne et al., JAMA 2024) specifically examined maintenance dosing and showed that hair loss reports clustered in the active weight loss phase, with new reports tapering during the maintenance period when weight had stabilized.

Why tirzepatide shows more hair loss than semaglutide

The cleanest comparison comes from indirect cross-trial data:

Molecule	Trial	Maximum dose	Weight loss	Alopecia
Semaglutide	STEP 1	2.4 mg weekly	14.9%	~3%
Tirzepatide	SURMOUNT-1	15 mg weekly	22.5%	5.7%

SURMOUNT-5 (Aronne et al., 2025) directly compared tirzepatide 15 mg to semaglutide 2.4 mg in a head-to-head trial. Tirzepatide produced significantly more weight loss (20.2% vs 13.7% mean). Alopecia rates were higher in the tirzepatide arm, consistent with the indirect comparison.

The simplest explanation: hair loss in this class is a downstream consequence of rapid weight loss, not a unique property of any particular GLP-1 or GIP/GLP-1 molecule. More weight loss creates more metabolic stress, which pushes more follicles into telogen.

The GIP receptor question

One mechanistic question worth raising: tirzepatide activates both GLP-1 and GIP receptors. Semaglutide only activates GLP-1. Could the additional GIP component contribute to alopecia independent of weight loss?

The evidence is thin. GIP receptors are expressed in many tissues, including some skin cells, but there is no specific literature linking GIP receptor activation to hair follicle effects. The cleanest piece of evidence against a GIP-specific mechanism: the dose-response curve in SURMOUNT-1 tracks weight loss rather than absolute GIP exposure. If GIP activation drove alopecia directly, the relationship would be different in shape.

This remains a theoretical possibility but not a clinically actionable one. There is no reason to avoid GIP/GLP-1 dual agonists specifically because of hair concerns at this point.

The dose-response curve and what it means for users

The SURMOUNT-1 dose-response pattern is clinically useful. It suggests that a tirzepatide user concerned about hair loss has a meaningful lever: stay at a lower maintenance dose once adequate weight loss has been achieved.

A patient who reaches their goal weight at 5 mg, or who tolerates 10 mg without further benefit at higher doses, can stop the titration. The 5 mg dose produces about two-thirds of the maximum weight loss with about 60% of the alopecia incidence.

Compare to patients who titrate aggressively to 15 mg seeking maximum loss. Those patients accept the highest alopecia risk for an additional 7-percentage-point weight benefit.

This is a clinical conversation, not a recommendation. The right dose depends on weight loss goals, side effect tolerance, cost, and supply considerations. The point is that the dose is a real variable with downstream hair implications.

Real-world FAERS data and post-marketing signals

The FDA Adverse Event Reporting System has accumulated alopecia reports for tirzepatide since its 2022 approval. The 2024 pharmacovigilance review by Hicks et al. in JAMA Dermatology identified disproportionate alopecia reporting for tirzepatide compared to non-GLP-1 medications, with reporting odds ratios in the moderate range.

The same caveats apply to FAERS as they do for semaglutide: voluntary reporting, sensitivity to media coverage, and tendency to overstate uncommon events. The signal is real but probably inflated relative to the trial incidence.

The clinical takeaway: trial data and post-marketing data tell consistent stories. Tirzepatide produces hair loss in a meaningful minority of users, the pattern matches telogen effluvium, and the magnitude tracks with weight loss.

The clinical presentation in tirzepatide users

The phenotype reported by tirzepatide users matches the general telogen effluvium pattern with some specific features:

• Diffuse shedding across the entire scalp, more noticeable at the part line and crown
• Onset typically 3 to 5 months into treatment, coinciding with the period of fastest weight loss
• Visible "shedding events" when brushing or showering, with hair coming out in noticeably larger amounts than baseline
• Often accompanied by mild fatigue, which may reflect concurrent nutritional inadequacy
• Resolution typically 3 to 6 months after weight stabilization

Patient forums and Reddit threads on tirzepatide use show a similar reporting pattern. Common comments describe finding hair "everywhere" during peak shedding, then noticing regrowth as short fine hairs along the hairline once weight stops changing.

Comparison: Zepbound vs Wegovy vs compounded options

From a hair-loss perspective:

Option	Active ingredient	Max dose	Expected weight loss	Alopecia incidence
Zepbound	Tirzepatide	15 mg	~22.5%	~5.7%
Wegovy	Semaglutide	2.4 mg	~14.9%	~3%
Ozempic (off-label)	Semaglutide	2 mg	~12-14%	~2-3%
Mounjaro (off-label)	Tirzepatide	15 mg	~22.5%	~5.7%
Compounded semaglutide	Semaglutide (503A)	Variable	Variable	Not formally measured
Compounded tirzepatide	Tirzepatide (503A)	Variable	Variable	Not formally measured

Mounjaro and Zepbound are the same molecule; Ozempic and Wegovy are the same molecule. The brand differences reflect approved indications, not drug substance. Compounded versions use the same active pharmaceutical ingredients but are not FDA-approved and have not been studied in pivotal trials.

If hair loss is the primary concern, semaglutide-based regimens carry a lower probability of alopecia than tirzepatide-based ones. The tradeoff is smaller weight loss. Many patients find that the additional weight loss on tirzepatide is worth the higher hair risk; others prefer semaglutide for the gentler profile.

Risk factors that increase Zepbound hair loss probability

Within tirzepatide users, certain factors increase the probability of clinically significant shedding:

• Aggressive titration to 15 mg within the first 5 to 6 months
• Rapid weight loss exceeding 1 to 1.5% of body weight per week
• Baseline ferritin below 50 ng/mL
• Protein intake below 60 grams per day
• Total caloric intake below 1,000 per day
• Concurrent diagnoses: hypothyroidism, postpartum status, recent severe illness
• Female sex (female pattern hair loss is more sensitive to telogen effluvium triggers)
• Family history of androgenetic alopecia, which can be unmasked by transient effluvium

The modifiable factors are dose, titration speed, nutrition, and ferritin. Patients who optimize these levers can reduce their probability of shedding even at higher tirzepatide doses.

The contrary view: is there something tirzepatide-specific?

The dominant explanation for tirzepatide's higher alopecia rate is weight loss magnitude. But several arguments exist for a tirzepatide-specific contribution:

Argument 1: Speed of weight loss matters independently. Tirzepatide tends to produce faster early weight loss than semaglutide, not just more total loss. Rapid losses are more disruptive to the hair cycle than the same total loss spread over a longer period. If tirzepatide users lose more weight in the first 4 months than semaglutide users do over the same window, the trigger may be sharper.

Argument 2: GIP and follicle metabolism. The GIP receptor is involved in lipid metabolism and adipocyte function. A more pronounced effect on fat tissue could indirectly affect skin and follicle metabolism in ways that are not yet characterized. This remains speculative.

Argument 3: Patient population differences. SURMOUNT-1 enrolled patients with slightly higher mean BMI than STEP 1. Whether population differences explain part of the observed alopecia difference is unclear.

The counter to all of these: SURMOUNT-1 itself shows a dose-response that tracks weight loss within the tirzepatide arms. That internal consistency argues against a primary drug-specific effect.

The reasonable position: tirzepatide alopecia is largely explained by larger and faster weight loss, with possible minor contributions from drug-specific mechanisms that have not been clinically established.

Decision framework

If you are choosing between Zepbound and Wegovy and hair is a major concern: Wegovy carries roughly half the alopecia incidence based on trial data. The tradeoff is smaller weight loss.

If you are already on Zepbound at 15 mg and shedding: Consider dose reduction once goal weight is approached. Optimize protein and ferritin. Most cases are self-limited.

If you are considering starting Zepbound: Set up nutrition (protein, ferritin) before starting. Plan for the possibility of shedding 3 to 6 months in. Document hairline with photos.

If shedding becomes severe or persistent: Refer to dermatology. Reassess whether weight loss is continuing or has stabilized. The shedding cannot resolve until the trigger does.

FAQ

Does Zepbound cause hair loss?

Yes; SURMOUNT-1 reported 5.7% incidence at 15 mg versus 1% placebo.

Is Zepbound hair loss permanent?

Not typically. Telogen effluvium is reversible.

Is Zepbound worse for hair than Ozempic?

Statistically yes, by roughly a factor of two, but tied to larger weight loss rather than direct drug toxicity.

When does Zepbound hair loss start?

Usually 3 to 5 months after starting, coinciding with peak weight loss.

Does the dose matter?

Yes; the SURMOUNT-1 dose-response is clear. Lower doses produce less weight loss and less alopecia.

Should I switch to Wegovy?

An option worth discussing with your prescriber. The tradeoff is reduced weight loss benefit.

Does Mounjaro cause the same hair loss as Zepbound?

Yes; same molecule, same hair signal.

Will my hair grow back after stopping Zepbound?

Almost always. Recovery usually starts within 6 months of weight stabilization.

Related guides

• Does Ozempic Cause Hair Loss? What the Trial Data Actually Shows
• How to Stop Hair Loss From Ozempic: A Clinical Playbook
• How Long Does It Take for Zepbound to Work? The SURMOUNT-1 Timeline Mapped to Real Patients
• Does Zepbound Cause Blindness? Eye Safety for the Weight-Management Tirzepatide
• Does Zepbound Cause Cancer? Reading the Boxed Warning Against the Tirzepatide Evidence Base

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1)
2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. (STEP 1)
4. Aronne LJ, et al. Tirzepatide vs Semaglutide in Adults With Obesity: SURMOUNT-5. 2025.
5. Hicks BM, Filion KB, Yin H, et al. Pharmacovigilance signal detection for GLP-1 receptor agonists and dermatologic adverse events. JAMA Dermatology. 2024.
6. Eli Lilly. Zepbound (tirzepatide) Prescribing Information. Most recent revision 2024.
7. Eli Lilly. Mounjaro (tirzepatide) Prescribing Information. Most recent revision 2024.
8. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. Most recent revision 2024.
9. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatol Ther (Heidelb). 2019;9(1):51-70.
10. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
11. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2023;29(11):2909-2918.
12. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Tirzepatide alopecia reports queried May 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth company. The information in this article is educational and does not constitute personalized medical advice. Decisions about which GLP-1 to take, when to adjust dose, and how to manage side effects should be made in conversation with the clinician overseeing your treatment.

Compounded Medication Notice. Compounded tirzepatide is prepared by 503A pharmacies under state regulation. Compounded products are not FDA-approved and have not been studied in pivotal clinical trials. Adverse event rates from SURMOUNT-1 and related trials describe branded Zepbound and Mounjaro, not compounded formulations.

Results Disclaimer. The alopecia incidence figures cited here are population averages from controlled trials. Individual experience varies. Some patients on tirzepatide will experience no hair changes; others may experience more pronounced shedding than the average.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends has no affiliation with these companies and references them only for clinical clarity.